Anthracycline-based chemotherapy
Anthracycline-based chemotherapy has been studied in 1 paper since 2025: 1 observational study in people; 1 in the past year. The newest paper, Nov 1, 2025: “Changes in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First-Line Chemotherapy in Patients With Lymphoma”.
1 paper studies it4 findingsUpdated
“total lean mass decreased by 1.70 kg (95% CI -2.55 to -0.85, p = 0.0002)”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Danske Fysioterapeuter and 1 more
- Humans1
What did studies of Anthracycline-based chemotherapy find?
4Studies of Anthracycline-based chemotherapy measured 4 outcomes; the most studied are sit-to-stand performance (1 study), handgrip strength (1) and body fat percentage (1).
Sit-to-stand performance
upin humans1
1 study
Sit-to-stand performance
upin humans1
Anthracycline-based chemotherapy improves sit-to-stand performance in humans (+1.4 repetitions (95% CI 0.15 to 2.69, p = 0.03)).
“Sit-To-Stand performance increased by 1.4 repetitions (95% CI 0.15 to 2.69, p = 0.03)”
Human trialaggressive lymphoma6 monthsn = 58
Hematological oncology
Handgrip strength
downin humans1
1 study
Handgrip strength
downin humans1
Anthracycline-based chemotherapy impairs handgrip strength in humans (-1.93 kg (95% CI -3.15 to -0.71, p = 0.002)).
“handgrip strength decreased by 1.93 kg (95% CI -3.15 to -0.71, p = 0.002)”
Human trialaggressive lymphoma6 monthsn = 58
Hematological oncology
Body fat percentage
upin humans1
1 study
Body fat percentage
upin humans1
Anthracycline-based chemotherapy increases body fat percentage in humans (+2.3% (95% CI 1.19 to 3.41, p = 0.0001)).
“body fat percentage increased by 2.3% (95% CI 1.19 to 3.41, p = 0.0001)”
Human trialaggressive lymphoma6 monthsn = 58
Hematological oncology
Total lean mass
downin humans1
1 study
Total lean mass
downin humans1
Anthracycline-based chemotherapy decreases total lean mass in humans (-1.70 kg (95% CI -2.55 to -0.85, p = 0.0002)).
“total lean mass decreased by 1.70 kg (95% CI -2.55 to -0.85, p = 0.0002)”
Human trialaggressive lymphoma6 monthsn = 58
Hematological oncology